Sale!

CJC-1295 (No DAC / Modified GRF 1-29) + Ipamorelin

Made in the USA

Two Series. Local or Global Shipping

CJC-1295 (No DAC / Modified GRF 1-29) + Ipamorelin

Name: CJC-1295 (No DAC / Modified GRF 1-29) + Ipamorelin
SKU: CP10-CJC-1295-NO-DAC-IPAMORELIN-BLEND
Availability: InStock

Price range: $90.00 through $150.00

Modified GRF(1-29) + Ipamorelin combines two complementary GH-release pathways: GHRH-receptor signaling and GHS/ghrelin-receptor signaling. Research commonly tracks GH pulse dynamics, IGF-1, pathway synergy, and endocrine selectivity versus the individual components.

What this formula features: Modified GRF provides the GHRH signal, while Ipamorelin provides a GHS-receptor signal. Ipamorelin has demonstrated selective GH release in preclinical work with comparatively little ACTH or cortisol release at studied doses; however, controlled human evidence for this exact combination is limited.

Typical research readouts: Researchers typically compare GH pulse amplitude, secretion kinetics, IGF-1 response, receptor-pathway synergy, and endocrine selectivity versus either component alone. Combination effects should be measured directly rather than assumed from single-agent data.

This product is strictly for research purposes only. Not approved for human or animal use.

3 Day FAST Shipping

99%+ Purity Tests

Ships from Arizona & Worldwide

USA Lab Tested

Strength

Purchase Option

Clear

Location	Price

Location	Price

WHOLESALE KIT — IMPORTANT ORDER INFORMATION

This is a wholesale 10-vial program. Kits are fulfilled directly through our international manufacturing and fulfillment network rather than from standard retail inventory, allowing us to offer genuine bulk pricing.

Please review the following before adding a kit to your cart:

Longer processing time: Wholesale kit orders may require 5–10 business days of processing before carrier transit begins. This is longer than standard single-vial orders.
Ships internationally: Wholesale kits are fulfilled from Hong Kong and shipped worldwide. International transit and customs processing may add additional delivery time.
Wholesale packaging: Vials may arrive without individual retail packaging or retail-style labels. Product identification and batch information should be verified using your order details and the applicable COA / batch documentation.
Lyophilized powder appearance may vary: Freeze-dried powder may shift, fragment, or separate during transportation. Changes in the physical appearance of the lyophilized puck are not, by themselves, considered a product defect.

Read Full Wholesale Kit Details →

Required Confirmation

I understand that this is a wholesale 10-vial kit fulfilled from Hong Kong, that processing and delivery take longer than standard local-stock orders, that wholesale packaging may differ from retail packaging, and that the physical appearance of lyophilized powder may change during transit.

YOU MUST ACCEPT THE WHOLESALE KIT SHIPPING NOTICE BEFORE ADDING THIS PRODUCT TO YOUR CART.

Proudly Made in the USA

USA-manufactured and USA-tested research products with fulfillment from Arizona, the UK, Australia, Europe, or Hong Kong.

USA Manufactured

USA Lab Tested

Ships from Arizona, US

Description
Additional information

✓ Third-Party Lab Tested

Certificate of Analysis

Independent laboratory testing confirms purity and composition of this research peptide.

Endo Passed

99.640%

Purity

A2926075

Batch

August 2026

Date

View Certificate →

Overview

This blend combines Modified GRF(1-29), a GHRH-receptor agonist, with Ipamorelin, a selective growth-hormone secretagogue acting through the GHS/ghrelin-receptor pathway. The research rationale is complementary stimulation of the same endocrine output through two different receptor systems.

Research Reference: View compound profile on NIH PubChem

Research Focus

WHAT THIS FORMULA FEATURES

Modified GRF provides the GHRH signal, while Ipamorelin provides a GHS-receptor signal. Ipamorelin has demonstrated selective GH release in preclinical work with comparatively little ACTH or cortisol release at studied doses; however, controlled human evidence for this exact combination is limited.

EXPECTED RESEARCH READOUTS

Researchers typically compare GH pulse amplitude, secretion kinetics, IGF-1 response, receptor-pathway synergy, and endocrine selectivity versus either component alone. Combination effects should be measured directly rather than assumed from single-agent data.

Research endpoints described above reflect published or model-based scientific observations and are not guaranteed outcomes. This product is strictly for research purposes only. Not approved for human or animal use.

Blend Composition

PEPTIDE COMPONENTS

CJC-1295 no DAC: 5mg (Modified GRF 1-29)

Ipamorelin: 5mg (Pentapeptide)

Total Peptide: 10mg

Ratio: 1:1 Equal blend

PHYSICAL PROPERTIES

Form: White lyophilized powder

Solubility: Readily dissolves in water

Stability: Enhanced compared to native GHRH

Storage: Keep refrigerated 36‑46 °F (2‑8 °C)

Additional information

Weight	0.08 lbs
Dimensions	0.87 × 1.18 × 0.87 in
Peptide	Ipamorelin, Modified GRF(1-29) / CJC-1295 (No DAC)
Strength	10mg, 20mg
CAS Number	170851-70-4, 446036-97-1
PubChem CID	56841945, 9831659
Purity	≥99% (third-party HPLC and mass spectrometry verified)
Form	Lyophilized powder
Storage	Store at −20°C (−4°F) for long-term storage or 4°C (39°F) for short-term storage; avoid repeated freeze-thaw cycles.
Testing	Batch-specific COA included
Origin	Manufactured in the US
Purchase Option	Fast Stock — From 1 Vial, Global — 10 Vial Kit